<DOC>
	<DOCNO>NCT02450539</DOCNO>
	<brief_summary>The main purpose study evaluate effectiveness study drug know abemaciclib versus docetaxel participant stage IV squamous non-small cell lung cancer ( NSCLC ) previously treat platinum-based chemotherapy .</brief_summary>
	<brief_title>A Study Abemaciclib ( LY2835219 ) Participants With Stage IV Squamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Confirmed diagnosis stage IV NSCLC . Have progress platinumbased chemotherapy advanced disease . Have receive prior treatment docetaxel . Have availability adequate formalinfixed paraffinembedded ( FFPE ) tumor derive material . Have adequate organ function include hematology , renal , liver . Have good performance score ( 01 ) . Have measureable disease per RECIST 1.1 . Agree use reliable medically approve method birth control . Have receive prior treatment cyclin dependent kinase ( CDK ) 4 6 inhibitor participate clinical trial CDK 4 6 inhibitor treatment administer know . Are currently receive treatment clinical trial involve investigational product nonapproved use drug device . Have presence unstable central nervous system ( CNS ) metastasis . Have major surgery ( exclude biopsy ) &lt; 28 day initial dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>patient report outcome ( PRO )</keyword>
	<keyword>patient focus outcome ( PFO )</keyword>
	<keyword>biomarkers</keyword>
	<keyword>CDK 4 6</keyword>
</DOC>